| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424144100 | Receptor integral to or derived from a lymphocytic or lymphocytic-like cell (e.g., NK cell, etc.) | 56 |
| 20090028870 | Treatment of Hematologic Disorders - The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like. | 01-29-2009 |
| 20090068192 | Fully human antibodies against human 4-1BB - Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject. | 03-12-2009 |
| 20090068193 | Treatment And Prophylaxis With 4-1BB-Binding Agents - Materials and Methods for using 4-1BB agonists to treat or prevent autoimmune disorders, lymphoproliferative diseases, and allergies are provided. | 03-12-2009 |
| 20090117126 | Neutralising Antibody Molecules Having Specificity for Human IL-17 - The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule. | 05-07-2009 |
| 20090123477 | Antibodies - The invention concerns an isolated monoclonal antibody, which is specific and agonistic for CTLA-4, whereby the antibody does not bind to the C″D loop of CTLA-4. | 05-14-2009 |
| 20090186037 | METHODS FOR INHIBITING AN IMMUNE RESPONSE BY BLOCKING THE GP39/CD40 AND CTLA4/CD28/B7 PATHWAYS AND COMPOSITIONS FOR USE THEREWITH - The present invention provides a method for inhibiting an immune response and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection. | 07-23-2009 |
| 20090191213 | Compositions and methods for regulating NK cell activity - The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects. | 07-30-2009 |
| 20090214561 | Treatment method - The invention provides methods of treating autoimmune diseases by administration of a complete therapeutically effective amount of a CD20 specific antagonist as a single intravenous infusion. Retreatment may follow by the administration of a complete therapeutically effective amount of the CD20 specific antagonist by a single intravenous infusion, 4 to 6 months after the first administration. The CD20 specific antagonist preferably is a CD20 specific antibody, and the autoimmune disease preferably is rheumatoid arthritis. | 08-27-2009 |
| 20090269353 | Stimulation of T Cells Against Self-Antigens Using CTLA-4 Blocking Agents - Stimulation of T cells to respond to self antigens is achieved through a blockade of CTLA-4 signaling. CTLA-4 blocking agents are combined with antigen preparations, either alone or with additional immune response stimulating agents, in costimulation strategies to break immune tolerance and stimulate an enhanced T-cell response against self antigens. This enhanced response is useful for the treatment of non-immunogenic and poorly-immunogenic tumors, as well as other medical conditions requiring selective tissue ablation. | 10-29-2009 |
| 20090304705 | BIOMARKERS FOR CHRONIC TRANSPLANT DYSFUNCTION - The invention relates to the analysis and identification of genes that are modulated in transplant rejection. This alteration of gene expression provides a molecular signature to accurately detect transplant rejection. | 12-10-2009 |
| 20090304706 | ANTAGONIST ANTI-CD40 ANTIBODY PHARMACEUTICAL COMPOSITIONS - Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component. | 12-10-2009 |
| 20090317401 | Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2 - The present invention relates to biological and medical application of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) an of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD 160 compounds in the fields of EC angiogenesis, and NK and T cytokine production | 12-24-2009 |
| 20100080809 | GITR LIGAND AND GITR LIGAND-RELATED MOLECULES AND ANTIBODIES AND USES THEREOF - The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e.g., autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR. | 04-01-2010 |
| 20100098706 | MONOCLONAL ANTIBODY DIRECTED AGAINST THE HUMAN LDL RECEPTOR - The invention relates to a monoclonal antibody directed against the human LDL (Low Density Lipoprotein) receptor, in which the variable region of each of the light chains is coded by the murine nucleic acid sequence SEQ ID NO: 5, the variable region of each of the heavy chains is coded by the murine nucleic acid sequence SEQ ID NO: 7, or by nucleic acid sequences having a sufficient homology with the sequences SEQ ID NO: 5 and SEQ ID NO: 7 so that the nature and the affinity of the bond between the antibody and its antigene are not modified, while the constant regions of the light chains and the heavy chains thereof are constant regions from a non-murine species. | 04-22-2010 |
| 20100183621 | Fully human antibodies against human 4-1BB - Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject. | 07-22-2010 |
| 20100266605 | USE OF A CD28 BINDING PHARMACEUTICAL SUBSTANCE FOR MAKING A PHARMACEUTICAL COMPOSITION WITH DOSE-DEPENDENT EFFECT - The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (MAB) or of a mimetic compound of the same, for producing a pharmaceutical composition, wherein the dosage is below or above a defined dosage limit. | 10-21-2010 |
| 20100310573 | ANTI-CD4 ANTIBODY - An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. | 12-09-2010 |
| 20110070239 | ANTI-OX40L ANTIBODIES - This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C | 03-24-2011 |
| 20110076277 | METHODS OF IDENTIFYING ANTI-INFLAMMATORY COMPOUNDS - A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN | 03-31-2011 |
| 20110091472 | COMPOSITIONS FOR TREATING PSORIASIS - CD40 antagonists are used to prepare compositions, including pharmaceutical compositions, for treating autoimmune and neoplastic diseases in a mammal. The CD40 antagonist compositions are useful for reversing or substantially diminishing such autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis and psoriasis. | 04-21-2011 |
| 20110142846 | METHOD FOR DIAGNOSING AND TREATING EMPHYSEMA - The present invention provides methods for diagnosing a patient with emphysema or COPD by detecting the levels of EMAP II in a sample. Alternatively, methods are provided for determining the susceptibility of a patient to develop emphysema or COPD by detecting the levels of EMAP II in a sample. The levels of EMAP II may be determined by immunoassay techniques. The present invention also provides methods for treating patients with emphysema or COPD by administering a therapeutically effective amount of an EMAP II neutralizing compound. The compound may be an antibody, siRNA, antisense RNA or an antagonist of CXCR3. | 06-16-2011 |
| 20110177088 | Method for Treating and Diagnosing Hematologic Malignancies - The invention relates to methods for treating and diagnosing hematologic malignancies, Chronic lymphocytic leukemia and Small Lymphocytic Lymphoma in particular, using PD-1 ligands (PD-L1, PD-L2 or anti-PD-1 antibodies). | 07-21-2011 |
| 20110182903 | NOVEL SOLUBLE CD83 POLYPEPTIDES, FORMULATIONS AND METHODS OF USE - Compositions and methods for treating or preventing unwanted immune responses are provided. The compositions relate to novel soluble CD83 (sCD83) polypeptides and nucleic acids encoding such polypeptides, improved (sCD83) formulations, and the use of such polypeptides and formulations in the treatment or prevention of allergy, autoimmune disease and transplant rejection. A sCD83 polypeptide is provided, comprising SEQ ID NO:7 or an amino acid sequence having at least 70% identity to SEQ ID NO:7; wherein one or more of amino acid residues 12, 20, 85 and 92 of SEQ ID NO:7 is an amino acid other than cysteine; and optionally, one or more of amino acid residues 1, 2, 3, 4 and 130 are absent. | 07-28-2011 |
| 20110229486 | Monoclonal Antibodies Against NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 09-22-2011 |
| 20120039902 | Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo - The present invention relates generally to binding agents useful in the selective depletion of T cells in vivo. More specifically, the invention relates to ICOS-binding agents which once bound to ICOS expressed on the surface of cells, in particular ICOS-bearing activated T cells, result in the in vivo depletion of cells to which they are bound. Methods of treating T cell related diseases using said ICOS-binding agents, and pharmaceutical compositions comprising said ICOS-binding agents, a method of identifying an ICOS-binding agent, and monoclonal anti-ICOS antibodies capable of eliminating cells in vivo which express ICOS on their surface are also provided. | 02-16-2012 |
| 20120039903 | METHODS FOR SUPPRESSING AN IMMUNE RESPONSE OR TREATING A PROLIFERATIVE DISORDER - Disclosed herein are methods for suppressing an immune response in a subject, treating a neoplasm in a subject, or treating a fibroproliferative vascular disease in a subject, that includes administering to the subject a therapeutically effective amount of a 2-(4-piperazinyl)-substituted 4H-1-benzopyran-4-one compound, or a pharmaceutically acceptable salt thereof, having the structure of | 02-16-2012 |
| 20120207763 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases, particularly pyrrolopyrimidine compounds and derivatives are described which inhibit protein kinases. The organic compounds are useful in treating proliferative disease. | 08-16-2012 |
| 20130078257 | USE OF AN ACTIVE SUBSTANCE BINDING TO CD28 FOR PRODUCING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF B-CLL - The invention relates to the use of a superagonistic monoclonal antibody (mAb), which is specific for a naturally costimulatory receptor expressed on T cells, or a mimicry compound thereto, for producing a pharmaceutical composition for the treatment of diseases occurring with lacking costimulability of T cells, in particular of the B-CLL. | 03-28-2013 |
| 20130101597 | MODULATION OF NK CELL ANTIGEN SPECIFIC EFFECTOR ACTIVITY BY MODULATION OF CXCR6 (CD186) - The instant invention is based, at least in part, on the discovery that CXCR6 plays a critical role in antigen-specific effector function of NK cells. Accordingly, the invention provides, among other things, methods for modulation of antigen-specific NK cell effector function, methods for identifying modulators of antigen-specific NK cell effector function. | 04-25-2013 |
| 20130122015 | ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES - The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided | 05-16-2013 |
| 20130136749 | Human CTLA-4 Antibodies And Their Uses - The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies. | 05-30-2013 |
| 20130142807 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful. | 06-06-2013 |
| 20130230534 | Interferon Receptor 1 Antibodies And Their Uses - The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention. | 09-05-2013 |
| 20130330351 | ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES - The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided | 12-12-2013 |
| 20140086932 | METHOD FOR ENHANCING SPECIFIC IMMUNOTHERAPIES IN CANCER TREATMENT - Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer. | 03-27-2014 |
| 20140120110 | ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 - The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production. | 05-01-2014 |
| 20140220029 | COMBINED USE OF A MODULATOR OF CD3 AND A GLP-1 COMPOUND - Methods and uses for the prevention and intervention of Type 1 diabetes comprising administration of a modulator of CD3 and a GLP-1 compound. | 08-07-2014 |
| 20140234331 | HUMAN CTLA-4 ANTIBODIES AND THEIR USES - The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies. | 08-21-2014 |
| 20140248278 | ANTI-CD22 ANTIGEN BINDING MOLECULES TO TREAT LUNG CANCER AND PROSTATE CANCER - This invention provides methods for preventing, reducing, delaying or inhibiting the proliferation and/or growth and/or metastasis of lung cancers and prostate cancer that express or overexpress CD22 by contacting the lung cancer cell or prostate cancer cell with an antigen binding molecule that binds to CD22 expressed on the surface of the cancer cell. | 09-04-2014 |
| 20140294853 | ANTAGONISTIC DR3 LIGANDS - The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases. | 10-02-2014 |
| 20140314784 | ANTI-CXCR4 ANTIBODIES AND METHODS OF USE - The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4. | 10-23-2014 |
| 20140314785 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful. | 10-23-2014 |
| 20150064196 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof - The present disclosure provides hetero-bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). | 03-05-2015 |
| 20150064197 | METHODS OF MODULATING IMMUNITY - The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration. | 03-05-2015 |
| 20150125466 | METHODS RELATED TO CANCER TREATMENT - The present invention relates to method for predicting a subject's relative response to cancer immunotherapy treatment. The methods involve providing a sample comprising a tumor cell or a peripheral blood cell from the subject; measuring the expression level of matrix metalloproteinase-23 (“MMP-23”) by the tumor cell or the peripheral blood cell; comprising the measured expression level of MMP-23 with a control or standard value; and determining the subject's predicted response to cancer immunotherapy, where, based on said comparing, a higher MMP-23 expression level compared to the control or standard value predicts the subject will have a poor response to cancer immunotherapy. The present invention also relates to methods for increasing production of tumor infiltrating leucocytes (“TILs”) in a subject, methods of identifying a subject as a candidate for adoptive T-cell therapy using T-cells that primarily express KCa3.1 channels, and methods of treating a subject having melanoma by administering an MMP-23 inhibitor. | 05-07-2015 |
| 20150132316 | MONOCLONAL ANTIBODIES AGAINST NKG2A - The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders. | 05-14-2015 |
| 20150376278 | USE OF A CD28 BINDING PHARMACEUTICAL SUBSTANCE FOR MAKING A PHARMACEUTICAL COMPOSITION WITH DOSE-DEPENDENT EFFECT - The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (MAB) or of a mimetic compound of the same, for producing a pharmaceutical composition, wherein the dosage is below or above a defined dosage limit. | 12-31-2015 |
| 20160000909 | REDUCING SYSTEMIC REGULATORY T CELL LEVELS OR ACTIVITY FOR TREATMENT OF DISEASE AND INJURY OF THE CNS - A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session. | 01-07-2016 |
| 20160003847 | Detection and Treatment of Pancreatic, Ovarian and Other CD70 Positive Cancers - The application provides methods of diagnosis, prognosis, prophylaxis and treatment of ovarian, pancreatic and other cancers using antibodies that specifically bind to denatured CD70. | 01-07-2016 |
| 20160024218 | Method and Pharmaceutical Composition for use in the Treatment and Prediction of Myocardial Infarction - The present invention relates to a method for predicting the survival time of a patient suffering of myocardial infarction or the recurrence of a myocardial infarction in a patient who has suffered from a myocardial infarction comprising the steps consisting of i) determining the expression level of BAFF in a sample from said patient, ii) comparing said expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value. | 01-28-2016 |
| 20160129097 | METHOD OF PROCESSING A VETERINARY TUMOR VACCINE AND A VETERINARY TUMOR VACCINE PROCESSING KIT - The present invention provides methods for preparing and administering a tumor vaccine. The processes include resecting tumors and isolating tumor cells, followed by treatment with ultraviolet radiation to activate the tumor cells. Cells can then be mixed with an unmethylated single stranded oligodeoxynucleotide chain adjuvant to formulate a vaccine and then administered to a subject. The vaccines can be autologous, allogeneic or hybrids thereof to the subject. | 05-12-2016 |
| 20160130346 | KIR3DL2 IS A BIOMARKER AND A THERAPEUTIC TARGET USEFUL FOR RESPECTIVELY PREVENTING AND TREATING A SUBSET OF CUTANEOUS AND NON-CUTANEOUS PERIPHERAL T-CELL LYMPHOMAS - The present invention relates to a ligand molecule that specifically binds to KTR3DL2 at the surface of KTR3DL2 expressing malignant T-cells for the treatment of lymphomas. It also relates to the in vitro use of a level of expression of KIR3DL2 is a biomarker useful for diagnosing and/or monitoring a lymphoma. | 05-12-2016 |
| 20160168256 | MONOCLONAL ANTIBODY AND A METHOD THEREOF | 06-16-2016 |
| 20180021317 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER AND METHOD USING THEREOF | 01-25-2018 |
| 20190144538 | ANTI-Kv1.3 ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF | 05-16-2019 |
| 20220135666 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR - This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a S1P modulator. | 05-05-2022 |
